Carfilzomib
| CAS No. | 868540-17-4 | Cat. No. | BCP02588 |
| Name | Carfilzomib | ||
| Synonyms | PR 171;PR171;PR-171; | ||
| Formula | C40H57N5O7 | M. Wt | 719.91 |
| Description | Carfilzomib inhibits proliferation in a variety of cell lines and patient-derived neoplastic cells, including multiple myeloma, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Carfilzomib reveals enhanced anti-MM activity compared with bortezomib, overcome resistance to bortezomib and other agents, and acts synergistically with dexamethasone (Dex). Carfilzomib shoes preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | Proteasome | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.